Cytodyn Inc (CYDY OTCQB) stock market data APIs
$0.2823
0(0%)
as of December 23, 2025
Try our APIs with
free plan!
Cytodyn Inc Financial Data Overview
Price chart is built with
Anychart
CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. It is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. The company's leronlimab is currently under phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
Prev. Close
0.2823
Open
0.2838
High
0.2854
Low
0.2778
52 wk Range
0.11-0.49
Market Cap
360 M
Shares Outstanding
1 266 M
EPS
-0.0047
Beta
1.334
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Cytodyn Inc data using free add-ons & libraries
Get Cytodyn Inc Fundamental Data
Cytodyn Inc Fundamental data includes:
- Net Revenue:
- EBITDA: 7 281 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-29
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Cytodyn Inc News
New
CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium
Leronlimab treatment is associated with upregulation of PD-L1 in circulating tumor cells and cancer-associated macrophage-like cells Remarkably longer survival was observed in patients treated with l...
CytoDyn Announces Resolution of Class Action Lawsuit
VANCOUVER, Washington, Dec. 01, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized m...
CytoDyn secures $30M equity funding commitment
* CytoDyn (OTCQB:CYDY [https://seekingalpha.com/symbol/CYDY]) obtained a $30M funding commitment [https://seekingalpha.com/pr/20289715-cytodyn-secures-30-million-commitment-from-yorkville-advisors] ...
CytoDyn to Present at the LD Micro Main Event XIX Investor Conference
CFO Robert E. Hoffman to deliver company presentation on October 21, 2025 VANCOUVER, Washington, Oct. 09, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinica...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
